NIDHOG — Nidhogg Resources Holding AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK4.72m
- SEK3.85m
Brief: Eurocine Vaccines Says Immunose Flu Showed Good Safety In Older Adults
Brief: Eurocine Vaccines Gets Authorized To Conduct Phase I/II Clinical Study
Brief: Eurocine Vaccines Gets Proceeds Of SEK 32.8 mln Before Issue Costs
Brief: Eurocine Vaccines: First Nasal Influenza Vaccine Approved For Children Under 2
Brief: Eurocine Vaccines Q1 net loss widens to SEK 6.9 mln
Brief: Eurocine Vaccines: vaccine candidate Immunose FLU shows good safety in clinical study
Brief: Eurocine Vaccines: exercise of warrants brings proceeds of SEK 35.8 mln
Brief: Eurocine Vaccines: initiation of clinical study of nasal influenza vaccine candidate
Brief: Eurocine Vaccines receives another patent granted